Jigar V Desai, Amanda Urban, Doris Z Swaim, Benjamin Colton, Lilian W Kibathi, Elise M N Ferrè, Pamela Stratton, Melissa A Merideth, Sally Hunsberger, Theresa Matkovits, Raphael Mannino, Steven M Holland, Edmund Tramont, Michail S Lionakis, Alexandra F Freeman
Candida albicans causes debilitating, often azole-resistant, infections in patients with chronic mucocutaneous candidiasis (CMC). Amphotericin B (AMB) resistance is rare, but AMB use is limited by parenteral administration and nephrotoxicity. In this study, we evaluated cochleated AMB (CAMB), a new oral AMB formulation, in mouse models of oropharyngeal candidiasis (OPC) and vulvovaginal candidiasis (VVC) and in patients with azole-resistant CMC. OPC and VVC were modeled in Act1 -/- mice, and mucosal tissue fungal burden was assessed after once-daily treatment with CAMB, vehicle, or AMB-deoxycholate (AMB-d)...
June 14, 2022: Antimicrobial Agents and Chemotherapy